How this company measures up on the fundamentals that matter
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Trading characteristics and market positioning
Balance sheet strength and cash generation — the foundation of long-term value
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-09 | HENSON HEIDI | Director | 30,456 | — | |
| 2026-01-09 | KLOSK STEVEN MARK | Director | 30,456 | — | |
| 2026-01-09 | AZAB MOHAMMAD | Director | 30,456 | — | |
| 2026-01-09 | BROWN GREGORY B | Director | 30,456 | — | |
| 2026-01-09 | MAZZO DAVID J | Officer and Director | 81,000 | — | |
| 2026-01-09 | FLOWERS CYNTHIA LOUISE | Director | 30,456 | — | |
| 2026-01-09 | BUCK KRISTEN K | Officer | 25,000 | — | |
| 2026-01-09 | NISCO JAMES | Officer | 15,000 | — | |
| 2026-01-09 | IMAM TARIQ | General Counsel | 15,000 | — | |
| 2025-01-08 | HENSON HEIDI | Director | 15,789 | — |
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-14